Circulating tumour DNA profiling in early-stage non-small-cell lung cancer can be used to track single-nucleotide variants in plasma to predict lung cancer relapse and identify tumour subclones involved in the metastatic process.
- Christopher Abbosh
- Nicolai J. Birkbak
- Charles Swanton
